The most common adverse reactions reported in SINUS-24 and SINUS-52 were injection site reactions, conjunctivitis, arthralgia, gastritis, insomnia, eosinophilia, and toothache. These adverse reactions occurred in ≥1% of patients on DUPIXENT 300 mg Q2W + INCS and at a higher rate than placebo + INCS in a 24-week safety pool.1

Q2W, once every 2 weeks; INCS, intranasal corticosteroid.

view the safety data